In people at risk of heart failure (HF) enrolled in the Heart 'OMics' in AGEing (HOMAGE) trial, spironolactone reduced circulating markers of collagen synthesis, natriuretic peptides, and blood pressure and improved cardiac structure and function. In the present report, we explored factors associated with dyskalaemia.
Dyskalemia in people at increased risk for heart failure. findings from the heart 'OMics' in AGEing (HOMAGE) trial / Monzo, Luca; Ferreira, João Pedro; Cleland, John G F; Pellicori, Pierpaolo; Mariottoni, Beatrice; Hazebroek, Mark R; Collier, Tim J; Cuthbert, Joe J; Pieske, Burkert; Petutschnigg, Johannes; Ahmed, Fozia Z; Girerd, Nicolas; Clark, Andrew L; Cosmi, Franco; Staessen, Jan A; Heymans, Stephane; Rossignol, Patrick; Zannad, Faiez. - In: ESC HEART FAILURE. - ISSN 2055-5822. - 9:6(2022), pp. 4352-4357. [10.1002/ehf2.14086]
Dyskalemia in people at increased risk for heart failure. findings from the heart 'OMics' in AGEing (HOMAGE) trial
Monzo, LucaPrimo
;
2022
Abstract
In people at risk of heart failure (HF) enrolled in the Heart 'OMics' in AGEing (HOMAGE) trial, spironolactone reduced circulating markers of collagen synthesis, natriuretic peptides, and blood pressure and improved cardiac structure and function. In the present report, we explored factors associated with dyskalaemia.| File | Dimensione | Formato | |
|---|---|---|---|
|
HOMAGE dyskalemia.pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Creative commons
Dimensione
253.37 kB
Formato
Adobe PDF
|
253.37 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
